2023

Seo S, Healey B,  McLin R, Sacks N,  Benson C, Citrome L. Health disparities among patients with schizophrenia in an integrated healthcare system. Poster presentation, Psych Congress Elevate 2023, May 30-June 2, 2023.

Jensen I, Srivastava K, Minshall M, Kemp R. Estimating the lifetime burden of illness in patients with bronchiolitis obliterans syndrome. Abstract EE539. ISPOR 2023.

View Abstract

Bean K, Miller B, Jensen I, Fields C, Pang F. Evaluating the face validity of health state utility values (HSUVS) for metachromatic leukodystrophy (MLD). Abstract EE285. ISPOR 2023.

View Abstract

Bean K, Olaye A, Miller B, Jensen I, Dean R, Pang F. Direct cost analysis associated with the management of patients with metachromatic leukodystrophy (MLD) across nine European countries. Abstract EE408. ISPOR 2023.

View Abstract

Minshall M, Emden M, McLin R, Kemp P, Pontenani F, Cardosi L, Sacks N. The cost of non-cystic fibrosis bronchiectasis (NCFB) in patients with commercial insurance or Medicare coverage in the US. Poster presentation, ISPOR, April 2023.

Bonkowsky J, Healey B, Sacks NC, McLin R, Cyr P, Sawyer E, Stephen CD, Eichler F. Substantial burden of illness and mortality in men with adrenomyeloneuropathy. Poster presentation at American Academy of Neurology Annual Meeting, April 2023.

Eichler F, Bonkowsky J, Healey B, Sacks NC, McLin R, Cyr P, Sawyer E, Stephen C. The economic impact of adrenomyeloneuropathy (AMN) on direct medical costs in commercially insured US adults: A retrospective study. Poster presentation, ISPOR 27th International Meeting, Boston, MA, April 2023.

Bonkowsky J, Healey B, Sacks NC, McLin R, Cyr P, Sawyer E, Stephen C. Hospitalizations, clinical characteristics and mortality in adults with adrenomyeloneuropathy (AMN): A retrospective study. Poster presentation, ISPOR 27th International Meeting, Boston, MA, April 2023.

Dalvi T, Nørgaard M, Fryzek JP, Movva N, Pedersen L, Hansen HP, et al. 2023. Biomarker expression and survival in patients with non-small cell lung cancer receiving adjuvant chemotherapy in Denmark. PLoS ONE 18(4):e0284037; doi: 10.1371/journal.pone.0284037. PMID: 37040387.

View Abstract

Pang F, Dean R, Jensen I, Bean K, Fields C, Miller B. 2023. The cost-effectiveness of OTL-200 for the treatment of metachromatic leukodystrophy (MLD) in the US. Mol Gene Metab 138(2):107258; doi: 10.1016/j.ymgme.2022.107258.